OncoTraj: a public benchmark for longitudinal resistance prediction in EGFR-mutant non-small-cell lung cancer on osimertinib
OncoTraj establishes the first public benchmark for training machine learning models on longitudinal cancer patient data, aggregating 813 EGFR-mutant NSCLC cases across three clinical-genomic sources to standardize resistance prediction under osimertinib therapy. The dataset unlocks three locked evaluation tasks spanning binary progression classification, time-to-event regression, and multi-class outcome prediction, addressing a critical gap in computational oncology where predictable clonal evolution under drug pressure has lacked standardized benchmarking infrastructure. This work signals growing maturity in clinical ML by moving beyond isolated retrospective studies toward reproducible, multi-institutional evaluation frameworks that enable direct model comparison and accelerate development of clinically actionable resistance forecasting systems.
Modelwire context
ExplainerThe significance here is less about the ML methods themselves and more about data governance: by aggregating MSK-CHORD, AACR Project GENIE, and FLAURA trial data under locked evaluation splits, OncoTraj prevents the silent overfitting that has plagued prior retrospective oncology studies, where researchers could inadvertently tune models to the same data used for evaluation.
The challenge OncoTraj addresses, building reliable predictive systems over irregular, longitudinal patient trajectories, has a structural parallel in COGENT's work on continuous-time forecasting over irregular geospatial meshes (covered the same day from arXiv cs.LG). Both papers are fundamentally arguing that fixed-interval, discrete-time evaluation frameworks fail when the underlying process is continuous and non-uniform. The difference is that clinical data carries an additional constraint: you cannot simply generate more samples to stress-test your model, so the benchmark's locked splits do the work that simulation can do in physics domains. This is largely disconnected from the LLM-focused coverage elsewhere in today's archive.
Watch whether any of the three contributing institutions (MSK, AACR GENIE, FLAURA) publish independent model submissions to the benchmark within 12 months. If external groups outside those institutions submit results first, that confirms the benchmark achieved genuine community adoption rather than serving as a vehicle for the authors' own follow-on work.
Coverage we drew on
This analysis is generated by Modelwire’s editorial layer from our archive and the summary above. It is not a substitute for the original reporting. How we write it.
MentionsOncoTraj · MSK-CHORD · AACR Project GENIE · FLAURA · EGFR-mutant NSCLC
Modelwire Editorial
This synthesis and analysis was prepared by the Modelwire editorial team. We use advanced language models to read, ground, and connect the day’s most significant AI developments, providing original strategic context that helps practitioners and leaders stay ahead of the frontier.
Modelwire summarizes, we don’t republish. The full content lives on arxiv.org. If you’re a publisher and want a different summarization policy for your work, see our takedown page.